Research in the Division of Sleep Medicine
Emmanuel Mignot Lab
Dr. Mignot’s laboratory is located at the Stanford University Center for Sleep Sciences & Medicine (SSM) of which he serves as Director. The SSM administrative offices and laboratories moved to its newly renovated location in July 2013. Currently, Dr. Mignot’s laboratory occupies approximately 13,200’ of space. This area is used for molecular studies in humans and neurochemical studies of narcolepsy. His laboratory uses state of the art human genetics techniques, such as genome wide association, exome or whole genome sequencing in the study of human sleep and sleep disorders, with parallel studies in animal models. His laboratory is also interested in web-based assessments of sleep disorders, computer-based processing of polysomnography (PSG), and outcomes research.
Philippe Mourrain Lab
One major goal of the Mourrain lab is to elucidate the function of sleep at the synapse and its impact in synaptopathies such as Fragile X syndrome, autism spectrum disorders and Alzheimer’s disease. The Mourrain lab also investigates how sleep and the newly identified miR-9/TLX/Onecut pathway control brain and retina regeneration in mouse and zebrafish models. Reprogramming of endogenous neural stem cells is a critical step to develop safe and effective methods to replace damaged or dead neurons in many neurological disorders including synaptopathies and sleep disorders.
Seiji Nishino Lab
Our research focuses on understanding the etiology and pathophysiology of human sleep and circadian disorders using various animal models. We are especially interested in hypersomnia with various etiology. We also research and develop new sleep sensing technologies for humans and animals.
Sergiu Pasca Lab
The Pasca lab is interested in understanding the molecular and cellular mechanisms of neuropsychiatric disorders. We are using pluripotent stem cells (iPS cells) derived non-invasively from patients to generate in a dish specific regions of the human brain in a functional 3D structures known as organoids or assembloids, and employ live imaging, electrophysiology and other state-of-the-art technologies to identify disease phenotypes.
Jamie Zeitzer Lab
Dr. Zeitzer studies the development of human centric lighting as a countermeasure to the ills of the 24-hour society, and the biological underpinnings of sleep quality -- in essence, why we sleep.
Dr. Joseph Cheung
Dr. Cheung is a physician scientist and the recipient of an NIH NINDS K23 award, with a research focus on elucidating the neurobiological and genetic basis of hypersomnia disorders. In addition, he is a member of the American Academy of Sleep Medicine task force in actigraphy. His other research involves applying wearable and digital technologies to the study of sleep and disease phenotyping.
Dr. Makoto Kawai
Dr. Kawai is a physician scientist in the field of sleep medicine in aging and brain function. Using combined polysomnogram and novel neuroimaging technology, he aims to identify potential sleep biomarkers to investigate the mechanism of progression from normal aging to Mild Cognitive Impairment (MCI) or dementia. Additionally, he investigates the impact of sleep on cognitive/affective function or behavior abnormality in various neurodevelopmental and neurodegenerative disorders.
Dr. Mitchell Miglis
Dr. Miglis is a member of the International REM sleep behavior disorder (RBD) study group and is currently the Principal Investigator of an international NIH funded trial evaluating the risk of neurodegenerative disease in patients with RBD and autonomic failure. He is also lead investigator of a study evaluating the presence of autonomic dysfunction in Idiopathic Hypersomnia and the presence of sleep and autonomic disorders in patients with Ehlers-Danlos syndrome.
Dr. Gaurav Singh
Dr. Singh’s research interests include health outcomes regarding obstructive sleep apnea (OSA) and co-existing pulmonary diseases. In particular, as the director of chronic obstructive pulmonary disease (COPD) at Stanford, he has a specific interest in evaluating outcomes related to COPD-OSA Overlap Syndrome. His interests also include assessing outcomes with other pulmonary diseases that may overlap with OSA, including asthma, pulmonary hypertension, interstitial lung disease, and tracheobronchomalacia. These patients may require more advanced ventilation modalities, so this is an area that he is investigating as well.
Dr. Emmanuel During
Dr. During is co-investigator of a NIH funded international study evaluating the risk of neurodegenerative disease in patients with REM sleep behavior disorder, as well as a study on the role of microbiome (gut flora) in patients with Restless Legs Syndrome and its relation with iron metabolism. In addition, he is sub-investigator of a clinical trial evaluating a once nightly formulation of sodium oxybate in subjects with narcolepsy. His most recent interest pertains to home devices that can enhance slow wave sleep via auditory closed-loop stimulation. He is the Principal Investigator of a study investigating the accuracy of such a wearable home EEG device for the diagnosis of obstructive sleep apnea. Dr. During is designing several studies examining the effect of slow wave sleep enhancement on sleep quality, cognition and biological markers of Alzheimer's disease, as well as an industry-sponsored randomized controlled trial evaluating the impact of an immunomodulating agent on sleep architecture and sleep quality.
Dr. Clete Kushida
The Stanford Center for Human Sleep Research conducts clinical trials that improve ways to treat and manage sleep disorders. These studies aim to increase the safety and effectiveness of current and novel applications of sleep medicine, and to improve the quality of life of the greater populations of individuals with sleep disorders.
Dr. Logan Schneider
From a research perspective, Dr. Schneider’s long-term career plan is to refine the understanding of normal and dysfunctional sleep, much like the Epilepsy Phenome/Genome Project (EPGP) and Epi4K are doing for the enigmatic epilepsies. Insufficient sleep has been deemed a public health problem with poorly understood behavioral and physiologic sleep disorders lying at the core of the issue. He is currently using well-defined distinct and objective phenotypes (e.g. periodic limb movements, hypocretin-deficient narcolepsy) to acquire the analytic skills necessary to expand his knowledge of both signal processing and genetics, with the former enhancing his ability to identify and/or refine sleep phenotypes, and the latter facilitating the pathophysiological understanding of these phenotypes. As a consequence of a better link between symptoms/phenotypes, physiology, and genetic risks, more personally targeted and effective therapeutics can be developed to address the enriched spectrum of sleep disorders.